Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

uveal melanoma News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

Moderna's stock surged nearly 100% as their mRNA cancer vaccine, developed in partnership with Merck, demonstrated a significant delay in melanoma recurrence in a Phase 3 trial. The companies plan to submit the data to the FDA for potential approval.

A recent study published in PubMed highlights the prevalence of the MBD4 gene as a predisposing factor for uveal melanoma. This research contributes to the understanding of genetic risk factors associated with this rare eye cancer.

Researchers have developed a novel cyclic peptide radiotracer for FGFR1-targeted PET imaging in uveal melanoma. This advancement could enhance diagnostic capabilities for this rare form of eye cancer.

Recent updates on uveal melanoma treatment highlight advancements in targeted therapies and immunotherapy approaches. These developments aim to improve patient outcomes and address the unique challenges posed by this rare cancer.

Not rare diseases news,news about your rare disease.

Earlier

Moderna's stock surged nearly 100% as their mRNA cancer vaccine, developed in partnership with Merck, demonstrated a significant delay in melanoma recurrence in a Phase 3 trial. The companies plan to submit the data to the FDA for potential approval.

A recent study published in PubMed highlights the prevalence of the MBD4 gene as a predisposing factor for uveal melanoma. This research contributes to the understanding of genetic risk factors associated with this rare eye cancer.

Researchers have developed a novel cyclic peptide radiotracer for FGFR1-targeted PET imaging in uveal melanoma. This advancement could enhance diagnostic capabilities for this rare form of eye cancer.

Recent updates on uveal melanoma treatment highlight advancements in targeted therapies and immunotherapy approaches. These developments aim to improve patient outcomes and address the unique challenges posed by this rare cancer.

Not rare diseases news,
news about your rare disease.